skip to main menu

R&D Center

  • 연구소 소개
    • 1층
    • 2층
    • 3층
  • 연구분야
  • 핵심기술
    • Allograft Tissue
    • Silicone Polymer
    • Medical Device
    • Bio Technology
  • 특허현황

HomeR&D CenterCore technology

Core technology_Allograft Tissue

Bone Transplant Product

1. Substances such as homogeneous minerals, collagen and gelatin were separated and purified from the human
The human bone mainly consists of minerals and organic matter. Hans Biomed Corp. developed the demineralized bone (DBM) from the human bone, as well as developing a technology to separate and purify other active ingredients.
- The human bone-derived mineral separation and purification technology.The human bone is approximately 65% minerals, with the main substance being calcium phosphate. When processing the demineralized bone (DBM), which consist of organic substances, minerals from the human bone can also be extracted at the same time to maximize the value of the bone tissue donated by the donor. In addition, this allows extraction of excellent bone minerals, which are safe and biocompatible. Compared to commercial calcium phosphate products, which usually contain single substances, the human bone extracted natural minerals, separated and purified in this manner, contains other elements such as Na, Mg, Fe and K with the calcium phosphate. Hence, it produces faster bone regeneration of better bone when it is transplanted into the human body.
- Separation and purification technology of collagen and gelatin.Approximately 35% of the human bone is collagen. Hans Biomed Corp. developed a method to separate and purify collagen and gelatin from the human bone, which are highly biocompatible through acid processing, dialysis and hydrolysis. The collagen and gelatin substances can be used as main ingredients or supplementary ingredients for new product development.
2. Slow release pharmacological agent impregnated microsphere manufacture technology bone.
This is a Sol-gel process, which consists of manufacture of non-toxic calcium phosphate microspheres, which contain various pharmacological agents through ionic bonding. The impregnated pharmacological agents are slowly released from the calcium phosphate particles, to produce long-term treatment effect after a single transplant. For diseases such as osteoporosis, the limitation of the need to avoid chronic repeated pharmacological treatment is solved by this technology. The calcium phosphate bone filler that contains osteoporosis treatment agent can be combined with an appropriate carrier, and this complex filler can be used to effectively treat areas of bone fracture due to osteoporosis. It can also be used in dental implant procedures in patients aged 50 years and over who have osteoporosis or low bone density to restore week gingiva and significantly improve treatment outcome.
3. Biodegradable porous scaffold manufacture technology
The human skull has an excellent porous structure, making it a good bone transplantation material. However, the amount of skull that can be extracted from the human bone is small, limiting its use. To solve this problem, Hans Biomed Corp. used combined calcium phosphate and human bone derived minerals as raw materials to manufacture a porous scaffold that is similar to the human skull bone. This technology can be used for mass production of porous and biocompatible scaffolds.
4. Virus inactivation to establish safety of the biomaterials
In the case of bone damage due to trauma, tumor, congenital deformity or biological phenomena, the most widely used method of treatment is autograft of one’s own bone from another part of the body to the area of defect, allograft by transplanting chemically treated bone from another person, or xenograft by transplanting part of the bone from an animal Unlike other medical products, bone transplant materials have a potential for biological activation of endogenous or exogenous contaminants,  or contamination due to infection from viruses or other iatrogenic pathogens, leading to the debate about its safety for use. Hans Biomed Corp. produced a virus deactivated biomaterial to minimize viral infection risk while maintaining the effectiveness of the transplant material.Hans Biomed only uses virus-free biomaterials that are selected after strict selection criteria for manufacture, but if virus inactivation technology is used for product manufacture process as a preparation, the presence of virus in the raw material will lead to deactivated viruses in the final product, producing safe products.

Skin Transplant Product

1. 3 Dimensional Cell Culture Technology
The actual biological response of cells cultured in two dimensions are different to those that are cultured in three dimensions. Hence, there was a need for the development of 3-dimensional cell culture technology to accurately mimic the biological response of organisms. Hans Biomed has produced visible progress in 3-dimensional cell culture of keratinocytes and fibroblasts in human skin tissue, endothelial cells that form blood vessels, osteocytes in the bone, lipocytes and cartilage cells.  By using biocompatible macromolecules and the regeneration capability of the body, we developed a biological product that induces regeneration of tissues in the body and in situ regeneration to become more competitive in the era of tailored medicine. This will maximize tissue regeneration abilities by reducing the treatment and restoration time.
2. Acellular Dermal Matrix Processing Technology
The skin is divided into the epidermis, dermis and subcutaneous tissue. The epidermis, on the surface of the body, consist of the keratin layer, lucidum, granulosa, spinosum and the basal layer, is avascular and acts as a barrier from the outside as well as controlling the level of moisture. The dermis is made of the papillary layer and the reticular layer, and it is a scaffold that has elasticity, strength, sensitivity and nutrition supplying functions. The dermal matrix consist of collagen, elastin, blood vessels and fibroblasts. Hans Biomed holds the core technology of removing such cells without causing damages to the dermis or causing immunological rejection response, to promote skin regeneration by transplanting the dermal matrix.Hans Biomed has the technology to produce SureDerm and BellaGem, which are skin related products for human transplantation,  and has successfully commercialized these materials with a high degree of safety.
3. Virus inactivation technology for the dermal matrix
Autograft of one’s own skin tissue, allograft of another person’s skin tissue, or xenograft of animal skin tissue can treat areas of skin defect from wounds or burns. But the use of such biological materials is associated with safety issues due to the risk of infective agents.Hans Biomed developed the virus inactivation technology to assure safety of the transplantable materials by minimizing viral infection risk, while maintaining its effectiveness.Based on this core technology, factors that can trigger immune rejection response were removed from the raw materials that were selected by strict selection criteria, and virus inactivation technology was used to minimize the risk of infection. This produced a high quality product that is both safe and effective.
4. Gamma ray sterilization technology which minimizes tissue damage
Hans tissue technology research center (HITE) developed a method to minimize damage to the skin tissue components during gamma ray sterilization process.The storage solution where the skin tissues are stored in, contains vitamin C, vitamin C derivatives, or a mixture of vitamin C and its derivatives to minimize skin tissue damage during gamma ray sterilization.  The sterilized final skin tissue maintained the structure and function of various components including proteins and collagen, and there were no structural changes or damages to maintain the structure of the intrinsic tissue. Ascorbic acid (vitamin C) is a major component of collagen formation, which is needed for tissue growth and repair, as well as fracture healing. It strengthens the gums, promotes adrenal function, aids iron absorption and also has antioxidative properties, to convert oxidative substances to restorable form to prevent oxidation. It reduces cholesterol levels to prevent atherosclerosis to decrease hypertension. However, ascorbic acid itself is unstable for use, so AA2G (ascorbic acid 2-glucoside) which is a combination of ascorbic acid and glucose, can be used. This technology prevents collagen deformation during gamma sterilization, functions as the core composite of the structure, helps collagen formation to decrease the treatment duration and restore damaged tissue to effectively maximize tissue regeneration abilities.